I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the ...

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

A subtle ad about breast cancer self-checks led me to reflect on my own experience and the complex role of pharmaceutical companies in awareness.

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.